The use of biologicals is evolving, with anti-human epidermal growth factor receptor 2 (HER2) therapy promising in cancers with overexpression of HER2 in first line treatment and ramucirumab in second line treatment [19,20,21]. This evidence concerns the gene ERBB2 and cancer.